Skip to main content
Premium Trial:

Request an Annual Quote

Fisher s Dharmacon Licenses Kreutzer-Limmer RNAi Patents from Alnylam

NEW YORK, Jan. 5 (GenomeWeb News) - Alnylam has granted Dharmacon a non-exclusive license to its Kreutzer-Limmer patent family, enabling the Fisher unit to develop and sell certain RNAi research products and services covered by the patents, Alnylam said today.

 

The Kreutzer-Limmer family, owned by Alnylam, covers small interfering RNAs and their use to mediate RNAi in mammalian cells. Dharmacon is currently a provider of siRNA reagents, and the Alnylam IP  expands its portfolio of internally developed and in-licensed RNAi intellectual property.

Alnylam obtained the rights to the Kreutzer-Limmer patent family, which were awarded in Europe, when it acquired Ribopharma in July 2003. That company is now known as Alnylam Europe. The patent family includes EP Patent No. 1144623, which covers siRNAs up to 25 nucleotides in length having a sequence complementary to a target gene; and EP Patent No. 1214945, which covers compositions, methods, and uses of siRNAs with a length between 15 and 49 nucleotides.

 

Patents corresponding to these patents have been issued or are pending in many other countries, Alnylam said.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.